Last reviewed · How we verify
NCT05590195
Effect of PreforPro® on Urinary and Vaginal Health
Phase 3 trial testing Preforpro in Bacterial Vaginosis in 50 participants. Status unknown.
1 March 2025
Quick facts
| Lead sponsor | Jeremy Burton |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 May 2024 |
| Primary completion | 1 March 2025 |
| Estimated completion | 1 June 2025 |
Drugs / interventions tested
- Preforpro — full drug profile →
- Placebo
Conditions studied
- Bacterial Vaginosis — all drugs for Bacterial Vaginosis →
- Bacterial Infections — all drugs for Bacterial Infections →
- Bacterial Vaginosis | Vaginal | Microbiology — all drugs for Bacterial Vaginosis | Vaginal | Microbiology →
- Vaginal Infection — all drugs for Vaginal Infection →
Sponsor
Jeremy Burton — full company profile →
Who can join
Adults 18 to 45, female only, with Bacterial Vaginosis or Bacterial Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will investigate the effects of PreforPro® (prebiotic and bacteriophages (LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae, greater \> 6.7 X 107 PFU/gram) on bacterial vaginosis.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Regulations of phage therapy across the world.
Yang Q, Le S, Zhu T, Wu N. · · 2023 · cited 86× · PMID 37869667 · DOI 10.3389/fmicb.2023.1250848 -
Emerging antimicrobial therapies for Gram-negative infections in human clinical use.
Hickson SM, Ledger EL, Wells TJ. · · 2025 · cited 11× · PMID 40016340 · DOI 10.1038/s44259-025-00087-2 -
Antimicrobial Resistance: The Answers.
Millar BC, Cates MJ, Torrisi MS, Round AJ, et al · · 2026 · PMID 41727556 · DOI 10.3389/bjbs.2026.15559 -
A Century of Bacteriophages: Insights, Applications, and Current Utilization.
Dkhili S, Ribeiro M, Slama KB. · · 2025 · PMID 41301576 · DOI 10.3390/antibiotics14111080
Verify or expand the search:
- PubMed search for NCT05590195
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bacterial Vaginosis
Currently open trials in the same condition.
- NCT07234786 — Clinical Study of a Vaginal Gel for the Treatment and Prevention of Vaginal Infections · NA · recruiting
- NCT06458543 — Optimization of Bacterial Vaginosis Treatment in Women of Reproductive Age · Phase 4 · recruiting
- NCT06263465 — Precision Vaginal Microbiome Transplantation in Women With Bacterial Vaginosis · NA · recruiting
- NCT05753813 — Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome · EARLY_PHASE1 · recruiting
- NCT06616168 — Urogenital Infections in Women of Reproductive Age and the Activity of 4-Thiazolidinone Derivatives Against Pathogens · Phase 1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05590195 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jeremy Burton
- Last refreshed: 9 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05590195.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing